Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
RVPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.49 - $4.28
Previous CloseN/A
Volume1.63M
Average Volume (3M)814.72K
Market Cap
$39.97M
Enterprise Value$62.66M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.88
Next Earnings
May 19, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding46,739,950
10 Day Avg. Volume620,505
30 Day Avg. Volume814,724
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.54
Forecast
1Y Price Target
$11.25Price Target Upside1208.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Reviva Pharmaceuticals Holdings News
PremiumCompany Announcements
Reviva Pharmaceuticals Reports 2024 Financial Results
PremiumCompany Announcements
Reviva Pharmaceuticals Delays Annual Report FilingPremiumPre-Earnings
Is RVPH a Buy, Before Earnings?
PremiumCompany Announcements
Reviva Pharmaceuticals Approves Executive Compensation Changes---
Bulls Say, Bears Say
Bulls Say
Clinical Data OutcomesPreliminary data from the OLE study included positive safety data with no side effects impacting more than 5% of patients and a favorable dropout rate compared to other approved drugs.
Drug EfficacyBrilaroxazine has better efficacy, fewer side-effects, higher patient compliance, and easy dosing compared to existing alternatives for the treatment of schizophrenia.
Market PositioningBrilaroxazine is expected to be competitively positioned against Cobenfy and other agents, assuming similar results in future RECOVER-2 data.
Bears Say
Financial ConstraintsThe company will likely need additional capital in order to move its clinical programs forward.
Funding ChallengesFunding constraints have delayed the P3 launch and management is yet to address capital.
Valuation ConcernsAcquisition of rival for massive premium serves to emphasize significant unwarranted valuation discrepancy.
---
Ownership Overview
4.49%
Insiders
3.23% Mutual Funds
5.02% Other Institutional Investors
83.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.48 and its highest was $4.28 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $39.97M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is May 19, 2025 which is in 21 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Mar 31, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.204 by $0.064.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.21.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 46,739,950 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.204. Following the earnings report the stock price went down -34.737%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in RVPH
---
Reviva Pharmaceuticals Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (1208.14% Upside)
$11.25 (1208.14% Upside)
Blogger Sentiment
Bullish
RVPH Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 684.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.30%
12-Months-Change
Fundamentals
Return on Equity
-916.17%
Trailing 12-Months
Asset Growth
-34.59%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
---
RVPH Stock 12 Month Forecast
Average Price Target
$11.25
▲(1208.14% Upside)
Technical Analysis
Dyadic International
―
Connect Biopharma Holdings
―
PepGen Inc.
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Best Analysts Covering RVPH
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-58.79%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.79% per trade.
---